Provided By PR Newswire
Last update: Mar 10, 2025
NEW YORK, March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Industries, Inc. The firm is concerned about conflicts relating to Checkpoint's controlling shareholder, Fortress Biotech, Inc. (Nasdaq: FBIO), which has secured special benefits in the deal.
Read more at prnewswire.com4.26
+0.03 (+0.71%)
2.13
+0.13 (+6.5%)
Find more stocks in the Stock Screener